On June 27, 2025 Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") reported that, pursuant to a securities purchase agreement (the "Purchase Agreement") with Blue Harbour Asset Management L.L.C-FZ ("Blue Harbour"), it has completed a private placement of the Company’s newly designated Series C Convertible Preferred Stock (the "Preferred Stock") (Press release, Titan Pharmaceuticals, JUN 27, 2025, View Source [SID1234654158]). Pursuant to the Purchase Agreement, Blue Harbour purchased 60,000 shares of Preferred Stock for an aggregate purchase price of $600,000. The shares have a conversion price of $3.40.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Certificate of Designations authorizing the Preferred Stock contains a beneficial ownership conversion "blocker" that prevents Blue Harbour from acquiring the lower of either (i) the maximum percentage of common stock permissible under Nasdaq rules and regulations without first obtaining shareholder approval or (ii) 19.99% of the Company’s outstanding common stock.

The shares being sold in this transaction do not involve a public offering and have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), in reliance on Regulation S thereunder. Titan and Blue Harbour have concurrently entered into a registration rights agreement (the "Registration Rights Agreement") pursuant to which Titan has agreed to provide certain registration rights upon the occurrence of certain events set forth in the Registration Rights Agreement. Additional information regarding the agreement can be found in an 8-K that was filed with the SEC: View Source

ARC Group Ltd. served as sole financial advisor to Titan in the private placement.

On June 27, 2025 Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), an oncology-focused life sciences company developing innovative therapies based on its uniquely biocompatible gold nanorod technology, reported that it has received ethics committee approval to proceed with its previously announced early feasibility study of its Targeted Hyperthermia Therapy ("THT") cancer treatment (Press release, Sona Nanotech, JUN 27, 2025, View Source [SID1234654155]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Sona CEO David Regan commented, "This ethics committee approval gives us the green light we’ve been waiting for to begin enrolling patients suffering from late-stage melanoma, for whom no other therapy has worked, to participate in our first-in-human clinical trial. Our clinical trial partner will now begin enrolling patients, and we will advise when a first dosing of our THT treatment has occurred. Sona’s CMO, Dr. Carman Giacomantonio, will provide clinical training and will observe the application of THT in the first patients enrolled."

The study is designed to assess safety, tolerability, and preliminary efficacy and will include two treatments of Sona’s THT, one week apart, for patients with advanced melanoma who are on, but have failed to respond to, a standard of care immunotherapy protocol. The study is anticipated to be conducted this summer with an initial read-out of final results expected by September, subject to enrollment rates.

On June 27, 2025 Imugene Limited (ASX: IMU), a clinical-stage immuno-oncology company, reported the first patient dosed in Australia, as part of the investigator sponsored Phase II Neo-POLEM clinical trial (Press release, Imugene, JUN 27, 2025, https://mcusercontent.com/e38c43331936a9627acb6427c/files/4621b5ea-5e19-3f10-0982-51c3e3f18e9e/1st_Patient_Dosed_in_Australia_PD1_Vaxx_neo_POLEM_PhII_Trial.pdf [SID1234654143]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Neo-POLEM is a Phase II study investigating the potential of PD1-Vaxx, a neoadjuvant PD-1 vaccine, to improve treatment outcomes for patients with mismatch repair-deficient / microsatellite instability high (dMMR/MSI-high) colorectal cancer. Approximately 15% of patients with colorectal cancer have the dMMR/MSI-high subtype.

The trial is an IST being conducted by Cancer Research UK Southampton Clinical Trials Unit in collaboration with Royal Surrey Hospital NHS Foundation Trust and the Australasian Gastro-Intestinal Trial Group (AGITG).

The primary objective of the study is to determine major pathological response rates, a measure of tumour size reduction post-treatment with PD1-Vaxx before surgery, with secondary objectives to assess the safety of PD1-Vaxx, evaluate biomarkers, and evaluate the objective response rates and overall survival.

This trial builds upon compelling early evidence that immunotherapy can deliver significant benefits in this patient population. The trial will recruit patients in both Australia and the United Kingdom.

Imugene’s CEO and Managing Director Leslie Chong said: "Dosing the first patient in the Neo-POLEM study represents hopeful treatment options for those suffering from these subtypes of colorectal cancer. We are encouraged by the potential of PD1-Vaxx to activate the body’s own immune system to fight cancer in this earliest stage of disease. Our focus remains firmly on improving outcomes for people living with this disease, and we’re grateful to the patients and clinical teams in Australia and the UK who are making this progress possible."

Colorectal cancer (CRC), also known as bowel cancer, is the third most common cancer, with a worldwide annual incidence of more than 1.2 million cases and a mortality rate of approximately 50%. About 80% of patients with colon cancer have localised and resectable disease at diagnosis.

On June 26, 2025 CDR-Life Inc., a biotechnology company developing highly selective T cell engagers (TCEs) to treat cancer and autoimmune diseases, reported CDR609 as its next clinical candidate. CDR609 is a novel TCE targeting LGR5, a surface antigen that presents a compelling opportunity for broad, tumor-specific therapeutic intervention in solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

LGR5 is a challenging and largely underexploited target in cancer immunotherapy. Unlike most other highly cancer-specific targets, LGR5 is not HLA-restricted, allowing CDR609 to potentially reach a broad patient population. Its high tumor specificity, a critical requirement for the successful use of TCEs, and broad expression across multiple high-prevalence tumor types, including colorectal, gastric, liver and pancreatic cancers, position CDR609 as a differentiated and scalable therapeutic approach.

"CDR609 embodies the key elements of our T cell engager platform: precision, potency and safety," said Christian Leisner, Ph.D., CEO of CDR-Life. "By targeting LGR5, we’re advancing a first-in-class molecule that could unlock significant value for patients with tumors that are currently underserved by immunotherapy."

CDR609 is built on CDR-Life’s proprietary M-gager platform, which enables the development of TCEs that address highly challenging but clean tumor targets and thus designed to minimize off-tumor effects. The company plans to initiate IND-enabling studies in the second half of 2025. The M-gager format and platform are currently being validated in the clinic in the CDR404 Phase 1 program, which is recruiting patients whose tumors express the intracellular target MAGE-A4.

(Press release, CDR-Life, JUN 26, 2025, View Source [SID1234666505])

On June 26, 2025 Sprint Bioscience reported that results from its DCPS program have been published in Leukemia, a scientific journal from Nature and one of the leading publications in hematology and oncology. The study strengthens the validation of DCPS as a therapeutic target in the treatment of Acute Myeloid Leukemia (AML).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The article identifies biomarkers associated with AML subtypes that respond particularly well to DCPS inhibition and sheds light on the underlying mechanisms of action. The results show that AML cases with DNMT3a and FLT3 ITD mutations and low levels of the related protein FHIT are particularly sensitive to DCPS inhibition. This facilitates patient selection and thereby increases the likelihood of positive treatment outcomes. Previous observations have shown that DCPS inhibitors have minimal impact on healthy cells and normal blood formation, with no signs of adverse effects.

"The potential for patient stratification combined with the favourable safety profile strengthens our conviction that DCPS inhibitors could become an effective and safe treatment option for AML," says Martin Andersson, CSO at Sprint Bioscience.

AML is a difficult-to-treat form of blood cancer in which current standard therapies—primarily chemotherapy—carry severe side effects and offer limited efficacy. Relapse is also common, underscoring the need for safer and more effective treatments.

The article is a collaboration between Sprint Bioscience AB, the research groups of Dr. Julian Walfridsson and Dr. Hong Qian at Karolinska Institutet, NeoTargets AB, and BioReperia AB. The Swedish Foundation for Strategic Research has partially funded it through an industrial PhD fellowship."

(Press release, Sprint Bioscience, JUN 26, 2025, View Source [SID1234660963])